We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Incyte’s Opzelura, First Topical JAK Inhibitor, Gets FDA Approval
Incyte’s Opzelura, First Topical JAK Inhibitor, Gets FDA Approval
Incyte has received the FDA’s approval for its Opzelura (ruxolitinib) cream for treatment of mild-to-moderate atopic dermatitis, making it the first topical JAK inhibitor to receive the agency’s blessing.